Press Releases

CAMBRIDGE, Mass. , July 9, 2012 (GLOBE NEWSWIRE) -- William M. McClements , a former executive at the Monitor Group , has joined Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) as Senior Vice President of Corporate Operations. McClements, who began at Merrimack in late 2011, is responsible for

CAMBRIDGE, Mass. , June 28, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc.  (Nasdaq:MACK) and the Cancer Treatment Centers of America® (CTCA) announced today that they have formed a unique and wide ranging partnership to advance their long-term vision of individualized treatment - where

Expansion to Include MM-398 in Combination With 5-Fluorouracil and Leucovorin Additional Arm Explores Broader Usage of MM-398 in a Setting Where Combination Therapy is Becoming More Common CAMBRIDGE, Mass. , June 27, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc.

Two Abstracts Selected for Oral Presentation Three Posters to be Presented, Each on Different Examples of Applying the Network Biology Approach to Therapeutic Development CAMBRIDGE, Mass. , June 26, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc.

CAMBRIDGE, Mass. , June 20, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) is set to join the broad-market Russell 3000 ® Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 25 , according to a preliminary list of

CAMBRIDGE, Mass. , June 18, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the election of John Mendelsohn , M.D., past president of The University of Texas MD Anderson Cancer Center to its Board of Directors. Merrimack is a biopharmaceutical company

Preclinical data on the mechanism of action of MM-398 in pancreatic cancer will be presented Preclinical data on MM-398's extended pharmacological profile will be presented Preclinical data on the pharmaceutical properties and pharmacokinetic profiles of MM-141 will be presented CAMBRIDGE, Mass.

CAMBRIDGE, Mass. , May 31, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy , President and Chief Executive Officer, is scheduled to present at the Jefferies 2012 Global Healthcare Conference on Tuesday, June 5, 2012 at 11:00 a.m.

Data on the safety and initial activity of MM-121 combined with erlotinib to be presented MM-111 multi-arm combination and MM-302 monotherapy Phase 1 designs to be presented CAMBRIDGE, Mass. , May 30, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc.

Significant Expansion in Merrimack's Pipeline Over the Last Six Months